StockNews.com Begins Coverage on Mirati Therapeutics (NASDAQ

StockNews.com assumed coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a research note published on Sunday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Several other analysts also recently weighed in on MRTX. Leerink Partnrs downgraded Mirati Therapeutics from an outperform rating to a market perform rating in […]

Related Keywords

United States , Leerink Partnrs , Benjamin Hickey , Jamie Christensen , Stifel Nicolaus , Scotiabank , Acadian Asset Management , Mirati Therapeutics Inc , Nasdaq , Bluepath Capital Management , First Horizon Advisors Inc , Quent Capital , Mirati Therapeutics , Free Report , Get Free Report , Horizon Advisors , Asset Management , Mirati Therapeutics Daily , Nasdaq Mrtx , Mrtx , Medical , Initiated Coverage , Stocknews Com ,